Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.


Saglam S. , Hacisahinogullari H. , Ozturk N., Kapran Y. , Gulluoglu M. , Turkmen C. , ...More

Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.20, no.5, pp.1201-5, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 5
  • Publication Date: 2015
  • Title of Journal : Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • Page Numbers: pp.1201-5

Abstract

Purpose: Benefits of somatostatin analogues have been mostly studied in mixed samples of patients including both functional and non-functional neuroendocrine tumors. This study aimed to examine the response of patients with non-functional metastatic or inoperable gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that received first-line treatment with the somatostatin analogue octreotide LAR.